Inspira Technologies stock hits 52-week low at $0.57

Published 07/04/2025, 15:48
Inspira Technologies stock hits 52-week low at $0.57

Inspira Technologies Oxy BHN Ltd. (IINN) stock has reached a new 52-week low, trading at $0.57, with technical indicators from InvestingPro suggesting the stock is in oversold territory. With a market capitalization of just $15.45 million and a beta of 2.14, the stock exhibits significant volatility. This latest price point marks a significant downturn for the company, which has seen its stock value decrease by 69.74% over the past year. Investors are closely monitoring the medical technology firm, known for its innovative respiratory support technology, as it navigates through a challenging period marked by this notable decline in its stock price. Financial health metrics from InvestingPro reveal the company is quickly burning through cash, with negative EBITDA of $11.1 million, though maintaining a current ratio of 2.02. The 52-week low serves as a critical juncture for Inspira Technologies, as market participants consider the company's future prospects and potential for recovery.

In other recent news, Inspira Technologies OXY B.H.N. Ltd. has shared significant updates regarding its strategic advancements and upcoming milestones. The company is focusing its financial resources on the development of the INSPIRA ART500 system, which aims to enhance oxygenation for patients with Acute Respiratory Failure without invasive mechanical ventilation. Inspira anticipates a prepayment from its U.S. distributor for the INSPIRA ART100 systems, suggesting potential near-term revenue. Meanwhile, Inspira Technologies has received a notice from Nasdaq about non-compliance with the minimum bid price rule, requiring the company to maintain a closing bid price of $1.00 or more for at least 10 consecutive business days by September 8, 2025, to avoid delisting.

Additionally, Inspira has reported promising initial results from its collaboration with Ennocure MedTech Ltd., showing a 95% reduction in bacterial presence using their novel bio-electronic patch in ex-vivo testing. This development could benefit the 250,000 patients who suffer from bloodstream infections related to intravenous lines annually. The bio-electronic patch enhances traditional IV dressings by preventing bacterial growth through physical means, potentially extending wear time and providing real-time monitoring capabilities. These updates highlight Inspira Technologies' ongoing efforts to innovate in respiratory support and infection prevention technologies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.